Shares of Constellation Pharmaceuticals (NASDAQ:CNST) had skyrocketed 66.7% as of 12:01 p.m. EDT on Wednesday. The huge gain came after MorphoSys (NASDAQ:MOR) announced that it will acquire Constellation for $1.7 billion.
MorphoSys was attracted to Constellation for its two lead pipeline candidates, pelabresib and CPI-0209. Constellation is currently evaluating pelabresib in late-stage clinical studies targeting myelofibrosis. It’s testing CPI-0209 in phase 2 clinical studies for treating blood cancer and solid tumors.
“Both pelabresib and CPI-0209 have broad potential, and we look forward to unlocking their full benefits for cancer patients,” said MorphoSys CEO Jean-Paul Kress. He referred to the deal as a “transformational acquisition” for MorphoSys as it increases its focus on hematology-oncology.
Two products are already on the market that use MorphoSys’ antibody technology. Johnson & Johnson won U.S. approval for Tremfya in 2017 for treating plaque psoriasis. Last year, MorphoSys won accelerated approval for Monjuvi in combination with Revlimid for treating diffuse large B-cell lymphoma.
Constellation’s share price is nearly at the $34 offered by MorphoSys, so the small biotech stock won’t move much higher. The acquisition is expected to close in the third quarter of this year.
This article represents the opinion of the writer, who may disagree with the “official” recommendation position of a Motley Fool premium advisory service. We’re motley! Questioning an investing thesis — even one of our own — helps us all think critically about investing and make decisions that help us become smarter, happier, and richer.
View more information: https://www.fool.com/investing/2021/06/02/why-constellation-pharmaceuticals-stock-is-skyrock/